Toronto, Ontario – The Newswire – November 3, 2023 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company") (TSXV:VPT) (OTC:VPTDF) is pleased to announce the results of its annual general and special meeting of shareholders held on November 1, 2023, in Toronto (the "Meeting"). Shareholders voted in favour of each of the matters considered at the Meeting, including electing each of Dr. George Adams, Robert Hodgkinson, Hugh MacNaught, Fiona Fitzgerald, Randy AuCoin, and Dr. Alvira Macanovic as directors of the Company to hold office for the ensuing year, appointing MNP LLP as the Company's auditors for the ensuing year, authorizing the board of directors to set their remuneration, and re-approving the Company’s stock option plan, all as described in the Company’s Information Circular dated October 2, 2023.

The CEO slide presentation and transcript are available on the Ventripoint website at: https://www.ventripoint.com/annual-meeting. 

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada. 

For further information, please contact: 

Jonathan Robinson

This email address is being protected from spambots. You need JavaScript enabled to view it.

416-669-1001 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.